<DOC>
	<DOCNO>NCT00293410</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , clofarabine cyclophosphamide , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase I trial study side effect best dose clofarabine cyclophosphamide treat patient relapsed refractory acute leukemia , chronic myelogenous leukemia , myeloproliferative disorder .</brief_summary>
	<brief_title>Clofarabine Cyclophosphamide Treating Patients With Relapsed Refractory Acute Leukemia , Chronic Myelogenous Leukemia , Myeloproliferative Disorders</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility tolerability administer clofarabine fractionate cyclophosphamide patient relapse refractory acute leukemia , chronic myelogenous leukemia , high-risk myeloproliferative disorder - Determine maximum tolerate dose clofarabine fractionate cyclophosphamide patient . - Determine toxic effect drug patient . Secondary - Obtain preliminary data biologic pharmacodynamic effect regimen marrow circulate leukemic blast patient . OUTLINE : This dose-escalation study . Patients stratify accord age ( adult v child ) . Patients receive cyclophosphamide IV 2 hour day 0 . Patients receive clofarabine IV 2 hour cyclophosphamide IV 2 hour day 1-3 8-10 . Treatment clofarabine cyclophosphamide repeat every 28 day least 2 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos clofarabine cyclophosphamide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 10 patient treated MTD . After completion study treatment , patient follow periodically 1 year . PROJECTED ACCRUAL : A total 70 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm leukemia myeloproliferative disorder , include 1 following : Acute myeloid leukemia ( AML ) subtype Treatmentrelated AML OR AML evolve myeloproliferative disorder ( MPD ) transform myelodysplastic syndrome Acute lymphocytic leukemia Acute progranulocytic leukemia Must eligible arsenic retinoic acid therapy Chronic myelogenous leukemia accelerate phase blast crisis Highrisk MPD , include follow : Myelofibrosis Chronic myelomonocytic leukemia 5 % 19 % blast Relapsed refractory juvenile myelomonocytic leukemia Relapsed and/or refractory disease progressive disease since last therapy No 3 prior induction regimen cytotoxic agent adult Must second relapse patient &lt; 21 year age PATIENT CHARACTERISTICS : ECOG performance status 02 ( adult ) OR Lansky 50100 % ( pediatric patient ) Bilirubin ≤ 1.5 mg/dL ( may elevate due hemolysis adult patient ) AST ALT ≤ 5 time upper limit normal Creatinine ≤ 2.0 mg/dL ( adult ) Normal renal function ( pediatric patient ) Cardiac function normal measure MUGA scan echocardiogram Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception least 6 month completion study treatment HIV negative No active graftversushost disease ≥ grade 2 No active , uncontrolled infection No fever No unstable CT scan lung , sinus , abdomen within past 4 week No arrhythmia ( atrial flutter fibrillation ) require medication No dyspnea rest minimal exertion No uncontrolled congestive heart failure No myocardial infarction within past 3 month No history severe coronary artery disease No significant concurrent disease , illness , psychiatric disorder would compromise patient safety compliance interfere consent , study participation , follow , interpretation study result PRIOR CONCURRENT THERAPY : Must recover acute toxic effect prior treatment More 30 day since prior investigational cytotoxic agent At least 3 day since prior azacitidine , thalidomide , hydroxyurea , imatinib mesylate , interferon At least 1 week since prior growth factor except epoetin alfa More 3 week since prior anticancer therapy No concurrent chemotherapy , radiotherapy , immunotherapy No concurrent anticancer investigational commercial agent No routine prophylactic use colonystimulating factor ( filgrastim [ GCSF ] sargramostim [ GMCSF ] ) Therapeutic use colonystimulating factor may consider discretion investigator No prolong use corticosteroid prevent treat emesis chemotherapeutic agent</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>childhood acute basophilic leukemia</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute eosinophilic leukemia</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
</DOC>